CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
1.775
-0.085 (-4.57%)
At close: Aug 13, 2025, 4:00 PM
1.800
+0.025 (1.41%)
Pre-market: Aug 14, 2025, 9:25 AM EDT
CytomX Therapeutics Employees
As of December 31, 2024, CytomX Therapeutics had 121 total employees, including 119 full-time and 2 part-time employees. The number of employees decreased by 1 or -0.82% compared to the previous year.
Employees
121
Change (1Y)
-1
Growth (1Y)
-0.82%
Revenue / Employee
$1,166,116
Profits / Employee
$396,554
Market Cap
292.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CTMX News
- 1 day ago - CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study - GlobeNewsWire
- 5 days ago - CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - CytomX Therapeutics: Updated Outlook For Late 2025 - Seeking Alpha
- 6 days ago - CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 14 days ago - CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 - GlobeNewsWire
- 2 months ago - CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma - GlobeNewsWire
- 3 months ago - CytomX Therapeutics: Doubling Overnight On Phase 1 Data - Seeking Alpha